Main Uses of Finasteride Portfarma

Finasteride Portfarma is a medication primarily used for the long-term treatment and control of Benign Prostatic Hyperplasia (BPH). This condition involves the non-cancerous enlargement of the prostate gland, which is common in aging men. The medication is designed to manage the symptoms associated with an enlarged prostate and to reduce the risk of complications related to the progression of the condition.

Treatment of Benign Prostatic Hyperplasia (BPH)

The primary therapeutic goal of this medication is to address the urinary difficulties caused by an enlarged prostate. As the prostate gland increases in size, it can exert pressure on the urethra, leading to various urinary symptoms. Finasteride Portfarma works by shrinking the enlarged prostate, which helps to alleviate these symptoms over time.

Specific benefits observed during treatment include:

• Improvement in Urinary Flow: By reducing the volume of the prostate gland, the medication helps to decrease the obstruction of the urethra, leading to a stronger and more consistent urinary stream.
• Reduction of Urinary Symptoms: Patients may experience a decrease in the urgency to urinate, a reduction in the frequency of urination (including during the night), and a diminished sensation of incomplete bladder emptying.

Long-term Benefits and Risk Reduction

Beyond symptom management, Finasteride Portfarma is used to alter the clinical progression of BPH. Continuous treatment is often associated with a lower likelihood of reaching a stage where the condition becomes acute or requires surgical intervention.

• Lower Risk of Acute Urinary Retention: The medication helps reduce the sudden inability to pass urine, a painful condition that often requires medical attention.
• Reduced Need for Surgery: By controlling the growth of the prostate and promoting its shrinkage, the treatment can decrease the probability that a patient will need surgical procedures such as transurethral resection of the prostate (TURP) or prostatectomy.

Mechanism of Action Summary

Finasteride Portfarma belongs to a class of medications known as 5-alpha reductase inhibitors. It functions by blocking the enzyme responsible for converting testosterone into dihydrotestosterone (DHT). Since DHT is the primary hormone driving the growth of the prostate gland, lowering its levels in the blood and the prostate tissue leads to a gradual reduction in the size of the gland.

Regulatory References

1. U.S. National Library of Medicine (NIH) via DailyMed

Finasteride Portfarma is a medicine with strictly defined eligibility criteria, as detailed in regulatory documents by authorities such as the FDA and EMA. Use is limited almost entirely to the adult male population.

Category	Regulatory Status (Official Statement)
Approved Population	Adult Men (18 years and older). Indicated for use in the male population only.
Contraindicated Populations	Women, particularly those pregnant or potentially pregnant (due to severe risk to a male fetus), the pediatric population (children and adolescents), and patients with known hypersensitivity to any component of the formulation.
Age-Group Rules	Approved for adult males. Contraindicated in children. No dosage adjustment necessary for older adults (geriatric use).
Organ Function Status	Renal Impairment: No dosage adjustment is necessary. Hepatic Impairment: Caution is advised due to extensive liver metabolism; the effects of liver insufficiency have not been studied.

Additionally, women who are pregnant or may potentially be pregnant must not handle crushed or broken tablets due to the risk of finasteride absorption through the skin.

Interactions with other medicines and products

The official regulatory documents for Finasteride Portfarma report that no drug interactions of clinical importance have been identified for the medicine's general use. Clinical studies formally assessed co-administration with common agents such as digoxin, warfarin, theophylline, propranolol, antipyrine, phenazone, and glibenclamide, and confirmed that these combinations resulted in no clinically meaningful interactions. The product is not considered to significantly affect the cytochrome P450-linked drug-metabolizing enzyme system.

A key restriction is the formal prohibition on co-administration with any other medication in the 5alpha-reductase inhibitor class. This rule is documented to prevent the potential for redundant or additive effects within the same pharmacological group.

Finasteride is primarily metabolized via the CYP3A4 enzyme system. Based on this metabolic pathway, regulatory information notes that known CYP3A4 inhibitors and inducers are expected to affect the plasma concentration of the medicine. Notably, the product’s bioavailability is not affected by food. A population-specific caution is also documented regarding patients with decreased hepatic function, as impaired clearance in the liver may result in elevated plasma concentrations of Finasteride.

Enzyme Inhibition and Molecular Targeting

Finasteride acts as a selective competitive inhibitor of the 5-alpha reductase enzyme (primarily the Type II isozyme). This mechanism involves the drug molecule physically binding to the enzyme's active site, blocking its core function. This domain describes the initial molecular interference required to modulate a key steroid pathway.

Modulation of the Androgen Metabolism Cascade

The selective enzyme blockade interrupts the metabolic conversion of the hormone Testosterone into its more potent derivative, Dihydrotestosterone (DHT). This systemic reduction in DHT levels alters the signaling dynamics within the body's androgen metabolism pathway, resulting in a sustained alteration of hormonal concentration.

Regulating Hormone-Dependent Tissue Activity

The resulting lower concentration of DHT limits the hormone's ability to bind to androgen receptors in targeted tissues, such as the scalp and prostate. This mechanistic cascade leads to the modulation of androgen signaling, which contributes to a subsequent physiological modification of tissue cellular activity.

How to Use Finasteride Portfarma

Finasteride Portfarma is administered according to standardized regimens. The medicine is available as an oral film-coated tablet and is taken by the oral route exclusively.

---

Official Dosing and Frequency

The appropriate strength and dose are determined by the specific condition being managed.

Indication	Standard Daily Dose	Frequency
Benign Prostatic Hyperplasia (BPH)	5 mg	Once daily
Male Pattern Hair Loss	1 mg	Once daily

Both dosage strengths are prescribed for once-daily administration. The overall treatment is structured as a long-term, continuous plan since the therapeutic effect is sustained only with consistent, uninterrupted use.

---

Administration Context and Special Conditions

Finasteride Portfarma may be taken with or without food, providing flexibility in daily scheduling. To maintain stable systemic levels, it is recommended that the dose be taken at approximately the same time each day. The tablet must be swallowed whole and should not be crushed or broken, as the film coating protects against potential exposure to the active ingredient.

No routine dosage adjustment is warranted for older adult patients or those with any degree of renal insufficiency; however, the medicine is not indicated for use in children or adolescents.

Finasteride Portfarma: Recent Clinical Evidence

The evidence base for Finasteride Portfarma is built upon research aimed at understanding how the medicine was studied in conditions linked to certain hormonal activity. The evidence summarized here comes from authoritative regulatory and aggregated scientific sources, and it solely describes the structure and reported findings of the research.

---

Evidence for use in Benign Prostatic Hyperplasia (BPH)

Research exploring BPH primarily includes randomized, double-blind, placebo-controlled trials (RCTs) and systematic reviews. Studies examined outcomes such as changes in standardized symptom scores, urinary flow rate, and prostate volume reduction. Findings describe patterns observed between study groups and control groups, including data related to the rate of major clinical events such as BPH-related surgery. Researchers noted that the measured changes in prostate volume and symptom scores were reported to be reversible upon discontinuation of the study medicine.

Evidence for use in Progressive Male Pattern Hair Loss

The evidence base for androgenetic alopecia was evaluated in controlled studies that monitored changes in total hair count within a target scalp area and used patient global photographic assessments. Controlled trials reported measurements of change in hair count and described patterns of improved hair appearance over multi-year periods. Researchers noted that the measured changes in hair count were reported to be reversible within twelve months after treatment discontinuation. Data regarding the measured outcomes in bitemporal hair recession have not been a primary focus of the existing controlled data.

Long-Term Research and Durability of Study Findings

Finasteride Portfarma was studied in trials designed to track outcomes over both short-term (12–48 months) and extended periods, with patient follow-up monitored for up to 10 years in observational studies. This research describes patterns related to the evolution of measured changes over multi-year periods. For BPH, long-term studies monitored data related to prostate size and the rate of major urological events. However, long-term effects are not fully established based on purely controlled randomized trials extending for a decade.

Studies on Specific Patient Groups and Remaining Uncertainty

Pivotal studies were conducted in large groups of adult men, including those aged 18 to early 40s for hair loss and men over 50 for BPH. Limited data is available from controlled trials specifically examining outcomes in men over the age of 50 for the hair loss indication. Data also remain insufficient for patients with specific comorbid conditions. The follow-up durations were limited in controlled trials, leaving long-term outcomes for certain markers not fully established. This evidence highlights what is known—and what is still uncertain—about the medicine’s studied outcomes.

Key Studies & References

1. Finasteride in the treatment of men with androgenetic alopecia: an update

Common questions about Finasteride Portfarma (FAQ)

---

Q: Do you have to take Finasteride Portfarma forever to keep the effects?

Studies and official product information indicate that the therapeutic changes achieved while taking the medicine are often not permanent. If the medicine is stopped, the measured effects, such as increased hair count or reduced prostate volume, are reported to be reversible and generally lost within 6 to 12 months.

Q: What are the most commonly reported side effects of Finasteride Portfarma?

Official regulatory documents describe common adverse reactions as those that occurred in 1% or more of patients in clinical trials. These commonly reported effects include decreased libido (sex drive), erectile dysfunction, decreased volume of ejaculate, breast enlargement (gynecomastia), breast tenderness, and rash.

Q: Can Finasteride Portfarma cause mood changes or depression?

Postmarketing reports, which track safety information after the medicine is in use, have documented adverse reactions classified as Psychiatric Disorders. These reports specifically include instances of depression and, in rare circumstances, suicidal ideation. This information is included in the medicine's official safety profile.

Q: Is Finasteride Portfarma approved for women's hair loss?

Finasteride Portfarma is indicated only for use in adult men. According to the official product information, it is explicitly not indicated for use in women. Furthermore, women who are or may become pregnant should be cautioned against handling crushed or broken tablets due to the risk of abnormal fetal development.

Q: How quickly can you expect to see any results from taking Finasteride Portfarma?

Clinical studies often measure initial outcomes after continuous use for periods such as 12 weeks (3 months) or 6 to 12 months before effects on hair count or prostate volume are typically reported. Regulatory documents indicate that consistent use over several months is necessary to assess the expected study outcomes.

Q: Can Finasteride Portfarma affect fertility or ability to have children?

Official data indicates that the medicine is associated with a decrease in ejaculate volume and total sperm per ejaculate, as observed in healthy volunteers. While these changes were generally reversible upon stopping the medicine, official documents note that the specific effect on male fertility has not been fully established.

Q: What happens if I stop taking Finasteride Portfarma suddenly?

Discontinuing the medicine is expected to lead to the reversal of the changes caused by the drug’s mechanism of action. This includes a rise in the hormone Dihydrotestosterone (DHT) and the subsequent gradual return of the condition being treated, such as the resumption of hair loss, over several months.

Q: Does Finasteride Portfarma interact with common supplements like multivitamins or protein powder?

Clinical studies have reported that no drug interactions of clinical importance have been identified with Finasteride when studied with commonly co-administered agents. Official documents do not typically include formal interaction study results for dietary supplements like multivitamins or protein powder.

Q: What is the typical age range of people who use Finasteride Portfarma?

The medicine is indicated only for use in adult men, meaning individuals 18 years and older. The clinical trials used to establish the evidence base included men aged 18 to early 40s for hair loss and men over 50 for the prostate condition. No dosage adjustment is typically required for older adult patients.

Q: Does Finasteride Portfarma cause weight gain or loss?

Official safety data includes postmarketing reports of adverse effects that mention both unusual weight gain and weight loss. These systemic effects have been documented in regulatory information, but they are not generally classified as common occurrences.

Q: Are there any documented interactions between Finasteride Portfarma and alcohol?

No drug interactions of clinical importance have been generally identified with Finasteride in the formal studies cited in official regulatory documents. Specific, formal studies examining the interaction between the medicine and alcohol are not universally included in official documentation.

Q: Is Finasteride Portfarma the same thing as Propecia or Proscar?

Finasteride is the single active ingredient in the medicine Finasteride Portfarma. It is the same active ingredient found in other brand-name products, such as Propecia and Proscar, which are used to manage hair loss or benign prostatic hyperplasia (BPH), respectively.

Q: Does Finasteride Portfarma affect blood pressure or heart rate?

Adverse events related to the cardiovascular system have been reported either in clinical trials or through postmarketing surveillance. These reports include instances of postural hypotension (a drop in blood pressure upon standing) and palpitations (an abnormal heart rhythm).

Q: How long does it take for Finasteride Portfarma to leave the body after stopping?

Pharmacokinetics data in official labeling indicates the medicine has a mean terminal half-life in plasma of approximately 5 to 6 hours in younger men and around 8 hours in men over 70. The half-life represents the time it takes for half of the drug concentration to be eliminated from the body.

Q: Does Finasteride Portfarma have interactions with cold and flu medicines?

Regulatory documents state that no drug interactions of clinical importance have been identified in clinical studies with a variety of commonly co-administered medicines. The medicine is mainly processed by the CYP3A4 enzyme system; specific interaction studies for common cold and flu remedies are not usually detailed in the official documents.

Q: Can Finasteride Portfarma cause issues with vision?

Postmarketing experience has documented rare instances of non-arteritic anterior ischemic optic neuropathy (NAION). This condition is a reported cause of sudden vision loss and is included in the official safety profile for the medicine.

Storage Conditions

Finasteride must be stored at Controlled Room Temperature (typically 20 C to 25 C), with permissible excursions up to 30 C. The product must be kept in the original container, which should be tightly closed to protect the tablets from moisture and light. Finasteride must be stored out of the sight and reach of children.

Special Handling and Disposal

Official labeling mandates a critical handling requirement: Women who are pregnant or may potentially be pregnant must not handle crushed or broken Finasteride tablets due to the risk of absorption. Intact tablets are film-coated for protection during normal handling.

Unused or expired Finasteride must be disposed of according to local regulations, such as using a drug take-back program. If no take-back option is available, the tablets can be mixed with an undesirable substance (e.g., dirt or coffee grounds), sealed in a container, and placed in the household trash.